drugset / Trial / NCT01006122

A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

NCT01006122

Phase 2 Completed 95 enrolled Pfizer
RandomizedCrossoverQuadruple-blindTreatment

Summary

Histaminergic agents are known to be involved with the sleep/wake cycle. This compound is a histaminergic agent which therefore may improve alertness and awakeness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy. Significant improvement in EDS when treated with this compound compared to placebo in patients with narcolepsy is hypothesized.

Timeline

Start
2009-11
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator PF-03654746 Small molecule 0.5 mg
Comparator PF-03654746 Small molecule 1 mg
Comparator PF-03654746 Small molecule 2 mg

Indications